Ruxolitinib for Cancer Cachexia
Ранняя фаза 1
Идёт, набор закрыт
NCT04906746
| Заболевание | Stage IV Non-small Cell Lung Cancer, Cachexia |
|---|
| Фаза | Ранняя фаза 1 |
|---|
| Спонсор | Tu Dan |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 10 участн. |
|---|
| Вмешательство | Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. |
|---|
| Дата начала | 23.02.2022 |
|---|
| Дата завершения | 27.09.2024 |
|---|
| Публикация результатов | 7.07.2026 |
|---|
Кратко
To assess toxicity with use of Ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.
Number of Non-small Cell Lung Cancer Cachexia Patients With Toxicity With the Use of Ruxolitinib
3 months · Participants
| Ruxolitinib 10mg | 0 Participants |
|---|
| Ruxolitinimb 15mg | 0 Participants |
|---|
| Ruxolitinib 10mg | 0 Participants |
|---|
| Ruxolitinimb 15mg | 0 Participants |
|---|
| Ruxolitinib 10mg | 2 Participants |
|---|
| Ruxolitinimb 15mg | 2 Participants |
|---|
Number of Non-small Cell Lung Cancer Cachexia Patients With Toxicity With the Use of Ruxolitinib
3 months · Participants
| Intervention Arm- Received Ruxolitinib | 0 Participants |
|---|
| Intervention Arm- Received Ruxolitinib | 0 Participants |
|---|
Analysis of Any Preliminary Evidence Suggesting That Ruxolitinib Suppresses Adipose and Lean Muscle Loss in Cancer Cachexia Patients
4 months · Participants
| 10 mg Ruxolitinib | 2 Participants |
|---|
| 15mg Ruxolitinib | 2 Participants |
|---|
| 10 mg Ruxolitinib | 0 Participants |
|---|
| 15mg Ruxolitinib | 0 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.